CD38 is a type II transmembrane glycoprotein involved in signaling and adhesion which is expressed mainly by immature hematopoietic cells and activated lymphoid cells. Central lymphatic channels of human small intestinal villi, the so-called lacteals, were coincidentally found to express CD38. Gastric and large intestinal mucosae, pancreas, liver, lung, nasal mucosa, kidney, thymus, palatine tonsil, Peyer's patches, appendix, and mesenteric lymph nodes, and rodent intestinal mucosa were subsequently examined for lymphatic expression of CD38. Cryosections prepared from biopsy or surgical resection specimens were immunostained with four different antibodies to CD38 combined with antibodies to von Willebrand factor and CD31 to differentiate lymphatics from blood vessels, or with antibody to lysosomal protein. Sections were evaluated by ordinary and confocal immunofluorescence microscopy. Jejunal cryosections were subjected to in situ hybridization for CD38. All CD38 antibodies decorated human lacteals, and some of these were positive for CD38 mRNA. Lymphatics draining Peyer's patches and appendix as well as afferent lymphatics of mesenteric lymph nodes expressed CD38 weakly. CD38 was not detected on lymphatics in other organs or in rodent lacteals. We propose that CD38 is a novel marker of human small intestinal lymphatic vessels.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s00428-002-0679-9 | DOI Listing |
Front Immunol
January 2025
Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, United States.
While durable antibody responses from long-lived plasma cell (LLPC) populations are important for protection against pathogens, LLPC may be harmful if they produce antibodies against self-proteins or self-nuclear antigens as occurs in autoimmune diseases such as systemic lupus erythematosus (SLE). Thus, the elimination of autoreactive LLPC may improve the treatment of antibody-driven autoimmune diseases. However, LLPC remain a challenging therapeutic target.
View Article and Find Full Text PDFBackground: Acute myeloid leukemia (AML) with RAM immunophenotype is a newly recognized high-risk AML immunophenotypic subcategory characterized by blasts with bright expression of CD56 and weak to absent expression of CD45, HLA-DR, and CD38, as first described by the Children's Oncology Group (COG). The relationship between AML-RAM and other CD56-positive acute leukemias is unclear. The goal of this study is to characterize the clinicopathological characteristics of AML with RAM phenotype and compare them with other CD56 co-expressing acute leukemias.
View Article and Find Full Text PDFInt J Reprod Biomed
November 2024
Urology and Nephrology Research Center, Research Institute for Urology and Nephrology, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
Background: Coronavirus disease 2019 (COVID-19) was identified in China in late December 2019 and led to a pandemic that resulted in millions of confirmed cases and deaths. The causative agent, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), uses distinct receptors and co-receptors to enter host cells. Vimentin has emerged as a potential co-receptor for SARS-CoV-2 due to the high level of vimentin expression in testis tissue.
View Article and Find Full Text PDFJ Transl Med
January 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 100730, China.
Background: Immunotherapy is a significant risk factor for severe COVID-19 in multiple myeloma (MM) patients. Understanding how immunotherapies lead to severe COVID-19 is crucial for improving patient outcomes.
Methods: Human protein microarrays were used to examine the expression of 440 protein molecules in MM patients treated with bispecific T-cell engagers (BiTe) (n = 9), anti-CD38 monoclonal antibodies (mAbs) (n = 10), and proteasome inhibitor (PI)-based regimens (n = 10).
Discov Oncol
January 2025
Division of Hematology/Oncology, The University of Texas Health Sciences Center at Houston, McGovern Medical School, 6431 Fannin Street, MSB 5.216, Houston, TX, 77030, USA.
The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for individuals with relapsed and refractory AML remains unfavorable. In response to the necessity for more efficacious therapeutic modalities, targeted immunotherapy has emerged as a promising advancement in AML treatment.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!